Prodrug technology: A promising breakthrough in CNS drug delivery :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Prodrug-based strategies enhance drug delivery across the blood–brain barrier

Prodrug approach Prodrug approach
Prodrug approach Prodrug approach

What's new?

Prodrug-based approaches show substantial improvements in brain drug delivery, with some candidates showing up to 15-fold higher brain uptake and 700-fold greater potency than their parent drugs.

Getting drugs into the brain is one of the biggest hurdles in treating central nervous system (CNS) disorders. Although several therapeutic agents show promise, the blood–brain barrier (BBB) acts as a protective filter, restricting their entry into brain tissue and often preventing them from reaching therapeutic concentrations.

Could modifying existing drugs help overcome this obstacle? Prodrug technology yields a promising approach by chemically modifying parent drugs to improve their delivery across the BBB. A recent systematic review explored advances in this strategy and evaluated its potential to improve CNS drug delivery. Sara Burhan Ahmed and other researchers analyzed 32 comparative experimental studies involving in vivo and in vitro investigations. The review included relevant studies issued over the preceding 15 years to assess different prodrug strategies for improving brain drug delivery.

The findings highlighted considerable improvements in brain exposure and pharmacological activity with selected prodrug formulations compared with their parent drugs. Three notable examples illustrated the potential of this approach:

  • Thyrotropin hormone prodrug: Extended the brain half-life to 47 ± 6 minutes, compared with just 4 ± 1 minutes for the parent drug.
  • ANG1005: Attained 12- to 15-fold higher brain uptake than unconjugated paclitaxel, illustrating improved delivery to the brain.
  • Abacavir-S2Me4: Exhibited 700-fold greater potency than its parent drug.

Overall, prodrug modification can address important limitations in conventional CNS drug delivery and may open novel avenues for developing therapies for neurological ailments. The prodrug approach offers an encouraging opportunity to tackle one of the biggest barriers in CNS drug development: inadequate drug penetration into the brain. Although experimental findings are encouraging, integrating these advances into routine clinical practice remains a major hurdle.

Additional studies are required to refine prodrug design and establish their safety and therapeutic potency in humans.

Source:

CNS & Neurological Disorders - Drug Targets

Article:

A Systematic Review of Recent Advances in Drug Delivery to the Central Nervous System Through Prodrug Approach

Authors:

Sara Burhan Ahmed et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: